CRISPR, Bayer JV tap CureVac for Cas9 mRNA constructs – FierceBiotech
FierceBiotech |
CRISPR, Bayer JV tap CureVac for Cas9 mRNA constructs
FierceBiotech CRISPR Therapeutics and its joint venture with Bayer have struck a deal with CureVac. The pact tasks CureVac with developing Cas9 mRNA constructs for use by CRISPR and joint venture Casebia Therapeutics in three in vivo gene-editing liver disease … CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer CRISPR Therapeutics (CRSP) Names Michael Tomsicek as CFO BRIEF—New mRNA collaboration for CRISPR, Casebia and CureVac |
